108 related articles for article (PubMed ID: 38617746)
1. Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review.
Marasco M; Dell'Unto E; Laviano A; Campana D; Panzuto F
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38783558
[TBL] [Abstract][Full Text] [Related]
2. Refractory carcinoid syndrome: a review of treatment options.
Riechelmann RP; Pereira AA; Rego JF; Costa FP
Ther Adv Med Oncol; 2017 Feb; 9(2):127-137. PubMed ID: 28203303
[TBL] [Abstract][Full Text] [Related]
3. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract][Full Text] [Related]
4. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
6. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
Regalla DKR; Deep O; Paluri RK
Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
[TBL] [Abstract][Full Text] [Related]
7. The evolving landscape of neuroendocrine tumors.
Bergsland EK
Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
[TBL] [Abstract][Full Text] [Related]
8. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.
Vitali E; Piccini S; Trivellin G; Smiroldo V; Lavezzi E; Zerbi A; Pepe G; Lania AG
Mol Cell Endocrinol; 2021 May; 527():111226. PubMed ID: 33675866
[TBL] [Abstract][Full Text] [Related]
9. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
Hofland J; Falconi M; Christ E; Castaño JP; Faggiano A; Lamarca A; Perren A; Petrucci S; Prasad V; Ruszniewski P; Thirlwell C; Vullierme MP; Welin S; Bartsch DK
J Neuroendocrinol; 2023 Aug; 35(8):e13318. PubMed ID: 37578384
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for advanced insulinomas and glucagonomas.
Alexandraki KI; Kaltsas GA; Grozinsky-Glasberg S
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343152
[TBL] [Abstract][Full Text] [Related]
11. Report of a Novel Molecular Profile in Malignant Insulinoma.
Burns L; Naimi B; Ronan M; Xu H; Weber HC
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835815
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C; Machida N; Honma Y; Okusaka T; Boku N; Kato K; Nomura S; Hiraoka N; Sekine S; Taniguchi H; Okano N; Yamaguchi K; Sato T; Ikeda M; Mizuno N; Ozaka M; Kataoka T; Ueno M; Kitagawa Y; Terashima M; Furuse J;
JAMA Oncol; 2022 Oct; 8(10):1447-1455. PubMed ID: 35980649
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
Kurita Y; Kobayashi N; Hara K; Mizuno N; Kuwahara T; Okuno N; Haba S; Tokuhisa M; Hasegawa S; Sato T; Hosono K; Kato S; Kessoku T; Endo I; Shimizu Y; Kubota K; Nakajima A; Ichikawa Y; Niwa Y
Intern Med; 2023 Jan; 62(2):159-167. PubMed ID: 35705270
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
